Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $42 from $45 and keeps an Overweight rating on the shares. The firm thinks setup ahead of next month’s cystic fibrosis readout is favorable, given high proportion of CFTR null patients, high cumulative dose, and expectation of greater benefit with longer term dosing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Optimistic Buy Rating for Arcturus Therapeutics Driven by Promising Developments in Cystic Fibrosis and COVID-19 Vaccine Programs
- Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress
- Arcturus Therapeutics reports Q2 EPS (34c), consensus (87c)
- Is ARCT a Buy, Before Earnings?
- Private Markets: Canva draws attention as IPO candidate following Figma debut